NantBioscience raises $100M

NantBioscience Inc. raised $100 million in equity financing, according to an SEC NantWorks LLC, is developing a pipeline of targeted therapies based on nanoparticle albumin-bound (nab) technology.

NantBioscience received $75 million up front in a January 2014 deal giving Celgene Corp. rights to two nab compounds in preclinical development. Soon-Shiong had been CEO of Abraxis Inc., which Celgene acquired in 2010 (see BioCentury Extra, Jan. 14, 2014). ...